NCT03072160 is a Phase 2 clinical trial of Pembrolizumab in Medullary Thyroid Cancer (MTC), sponsored by National Cancer Institute (NCI).

Who is sponsoring NCT03072160?

NCT03072160 is sponsored by National Cancer Institute (NCI).

What drugs are being tested in NCT03072160?

Interventions in NCT03072160: Pembrolizumab.

What condition does NCT03072160 study?

NCT03072160 studies Medullary Thyroid Cancer (MTC).

Is NCT03072160 still recruiting?

NCT03072160 is currently completed. Last updated 11 February 2021.

Are results published for NCT03072160?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-02-11 · How we verify

NCT03072160

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer

Completed Phase 2 Results posted Last updated 11 February 2021

What this trial tests

Phase 2 trial testing Pembrolizumab in Medullary Thyroid Cancer (MTC) in 17 participants. Completed in 22 November 2019.

Timeline

16 June 2017

Primary endpoint
22 November 2019

22 November 2019

Quick facts

Lead sponsor	National Cancer Institute (NCI)
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	17
Start date	16 June 2017
Primary completion	22 November 2019
Estimated completion	22 November 2019
Sites	1 location across United States

Drugs / interventions tested

Pembrolizumab (pembrolizumab) — full drug profile →

Conditions studied

Medullary Thyroid Cancer (MTC) — all drugs for Medullary Thyroid Cancer (MTC) →

Sponsor

National Cancer Institute (NCI)

Who can join

18 and older, any sex, with Medullary Thyroid Cancer (MTC). Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Clinical Response Primary · 2 years

Participants with medullary thyroid cancer were administered a programmed cell death protein 1 (PD1) inhibitor to determine if any experienced a 50% or greater decline in calcitonin levels. A calcitonin response is defined as participants with a ≥50% decline from baseline that is then confirmed on a subsequent calcitonin assessment at least one week later.

Group	Value	95% CI
Cohort 1: Cancer Vaccine	0
Cohort 2: Participants That Have Had No Vaccine	0

Percentage of Participants With a Partial Response and Complete Response by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Primary · 2 years

Participants were imaged by CT or MRI and followed for response using the Immune-Related Response Criteria (irRC). Partial Response is a ≥30% decrease in the sum of the largest diameter (SLD) compared with baseline confirmed by a consecutive assessment at least 4 weeks after the first documentation. Complete Response is a 100% disappearance of all lesions, whether measurable or not, and no new lesions, in two consecutive observations not less than 4 weeks from the date first documented.

Group	Value	95% CI
Cohort 1: Cancer Vaccine	0
Cohort 2: Participants That Have Had No Vaccine	0

Percentage Change in (Cluster of Differentiation 4 (CD4), CD8, Tregs, and Natural Killer (NK) Cells at Day 1 and 84 Days in All Participants Secondary · Day 1 and 84 days

Regulatory T-Cells (CD4, CD8, Tregs, and NK cells) in peripheral blood mononuclear cell (PBMC)s were measured by 7-color flow cytometry.

CD4

Group	Value	95% CI
All Participants at Day 1	34.73	12.5 – 53.5
All Participants at Day 84	33.95	9.7 – 46.5

CD8

Group	Value	95% CI
All Participants at Day 1	13.70	6.17 – 26.3
All Participants at Day 84	12.50	6.5 – 24.22

Tregs

Group	Value	95% CI
All Participants at Day 1	0.70	0.0 – 1.2
All Participants at Day 84	0.77	0.46 – 1.8

Group	Value	95% CI
All Participants at Day 1	10.47	6.6 – 17.7
All Participants at Day 84	10.26	4.6 – 19.5

Number of Participants With a Sustained Decline in Carcinoembryonic Antigen (CEA) Secondary · every 3 weeks while on treatment and post treatment, up to 2 years

A sustained 50% decline in CEA. A large magnitude decline in CEA may be associated with tumor responses.

Group	Value	95% CI
Cohort 1: Cancer Vaccine	0
Cohort 2: Participants That Have Had No Vaccine	0

Number of Participants With a Sustained Decline in Calcitonin Secondary · every 3 weeks while on treatment and post treatment, up to 2 years

A sustained 50% decline in calcitonin. A large magnitude decline in calcitonin may be associated with tumor responses.

Group	Value	95% CI
Cohort 1: Cancer Vaccine	0
Cohort 2: Participants That Have Had No Vaccine	0

Progression-free Survival (PFS) Secondary · 3 weeks for up to 2 years while on treatment than 2 weeks after last treatment

PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. Progression, assessed by the Immune-Related Response Criteria (irRC), is defined as at least 20% increase in the sum of the largest diameter (SLD) compared with nadir (minimum recorded tumor burden) and an increase of at least 5mm over the nadir, confirmed by a repeat,consecutive observations at least 4 weeks from the date first documented.

Group	Value	95% CI
Cohort 1: Cancer Vaccine	210
Cohort 2: Participants That Have Had No Vaccine	55

Overall Survival at 2 Years Secondary · 2 years

Percentage of participants who are alive at 2 years.

Group	Value	95% CI
Cohort 1: Cancer Vaccine	100
Cohort 2: Participants That Have Had No Vaccine	50

Number of Participants With Grade ≥1 Adverse Events Possibly, Probably, or Definitely Related to Pembrolizumab Secondary · Date treatment consent signed to date off study, approximately 25 months and 28 days for cohort 1 and 18 months and 12 days for cohort 2.

Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). Grade 1 is mild. Grade 2 is moderate. Grade 3 is severe or medically significant but not immediately life-threatening. Grade 4 is life-threatening; urgent intervention indicated. Grade 5 is death related to adverse event.

Acute kidney injury

Group	Value	95% CI
Cohort 1: Grade 1 Possibly Related	1
Cohort 1: Grade 1 Probably Related	0
Cohort 1: Grade 1 Definitely Related	0
Cohort 1: Grade 2 Possibly Related	1
Cohort 1: Grade 2 Probably Related	0
Cohort 1: Grade 2 Definitely Related	0
Cohort 1: Grade 3 Possibly Related	1
Cohort 1: Grade 3 Probably Related	0
Cohort 1: Grade 3 Definitely Related	0
Cohort 2: Grade 1 Possibly Related	0
Cohort 2: Grade 1 Probably Related	0
Cohort 2: Grade 1 Definitely Related	0

Alanine aminotransferase

Group	Value	95% CI
Cohort 1: Grade 1 Possibly Related	0
Cohort 1: Grade 1 Probably Related	0
Cohort 1: Grade 1 Definitely Related	0
Cohort 1: Grade 2 Possibly Related	1
Cohort 1: Grade 2 Probably Related	0
Cohort 1: Grade 2 Definitely Related	0
Cohort 1: Grade 3 Possibly Related	0
Cohort 1: Grade 3 Probably Related	0
Cohort 1: Grade 3 Definitely Related	0
Cohort 2: Grade 1 Possibly Related	0
Cohort 2: Grade 1 Probably Related	0
Cohort 2: Grade 1 Definitely Related	0

Allergic rhinitis

Group	Value	95% CI
Cohort 1: Grade 1 Possibly Related	1
Cohort 1: Grade 1 Probably Related	0
Cohort 1: Grade 1 Definitely Related	0
Cohort 1: Grade 2 Possibly Related	0
Cohort 1: Grade 2 Probably Related	0
Cohort 1: Grade 2 Definitely Related	0
Cohort 1: Grade 3 Possibly Related	0
Cohort 1: Grade 3 Probably Related	0
Cohort 1: Grade 3 Definitely Related	0
Cohort 2: Grade 1 Possibly Related	0
Cohort 2: Grade 1 Probably Related	0
Cohort 2: Grade 1 Definitely Related	0

Anemia

Group	Value	95% CI
Cohort 1: Grade 1 Possibly Related	0
Cohort 1: Grade 1 Probably Related	0
Cohort 1: Grade 1 Definitely Related	0
Cohort 1: Grade 2 Possibly Related	0
Cohort 1: Grade 2 Probably Related	0
Cohort 1: Grade 2 Definitely Related	0
Cohort 1: Grade 3 Possibly Related	0
Cohort 1: Grade 3 Probably Related	0
Cohort 1: Grade 3 Definitely Related	0
Cohort 2: Grade 1 Possibly Related	1
Cohort 2: Grade 1 Probably Related	0
Cohort 2: Grade 1 Definitely Related	0

Anorexia

Group	Value	95% CI
Cohort 1: Grade 1 Possibly Related	1
Cohort 1: Grade 1 Probably Related	0
Cohort 1: Grade 1 Definitely Related	1
Cohort 1: Grade 2 Possibly Related	0
Cohort 1: Grade 2 Probably Related	0
Cohort 1: Grade 2 Definitely Related	0
Cohort 1: Grade 3 Possibly Related	0
Cohort 1: Grade 3 Probably Related	0
Cohort 1: Grade 3 Definitely Related	0
Cohort 2: Grade 1 Possibly Related	0
Cohort 2: Grade 1 Probably Related	0
Cohort 2: Grade 1 Definitely Related	0

Arthralgia

Group	Value	95% CI
Cohort 1: Grade 1 Possibly Related	1
Cohort 1: Grade 1 Probably Related	0
Cohort 1: Grade 1 Definitely Related	0
Cohort 1: Grade 2 Possibly Related	0
Cohort 1: Grade 2 Probably Related	0
Cohort 1: Grade 2 Definitely Related	0
Cohort 1: Grade 3 Possibly Related	0
Cohort 1: Grade 3 Probably Related	0
Cohort 1: Grade 3 Definitely Related	0
Cohort 2: Grade 1 Possibly Related	0
Cohort 2: Grade 1 Probably Related	0
Cohort 2: Grade 1 Definitely Related	0

Aspartate aminotransferase

Group	Value	95% CI
Cohort 1: Grade 1 Possibly Related	2
Cohort 1: Grade 1 Probably Related	0
Cohort 1: Grade 1 Definitely Related	0
Cohort 1: Grade 2 Possibly Related	0
Cohort 1: Grade 2 Probably Related	0
Cohort 1: Grade 2 Definitely Related	0
Cohort 1: Grade 3 Possibly Related	0
Cohort 1: Grade 3 Probably Related	0
Cohort 1: Grade 3 Definitely Related	0
Cohort 2: Grade 1 Possibly Related	0
Cohort 2: Grade 1 Probably Related	0
Cohort 2: Grade 1 Definitely Related	0

Diarrhea

Group	Value	95% CI
Cohort 1: Grade 1 Possibly Related	2
Cohort 1: Grade 1 Probably Related	1
Cohort 1: Grade 1 Definitely Related	0
Cohort 1: Grade 2 Possibly Related	0
Cohort 1: Grade 2 Probably Related	0
Cohort 1: Grade 2 Definitely Related	0
Cohort 1: Grade 3 Possibly Related	0
Cohort 1: Grade 3 Probably Related	0
Cohort 1: Grade 3 Definitely Related	0
Cohort 2: Grade 1 Possibly Related	1
Cohort 2: Grade 1 Probably Related	0
Cohort 2: Grade 1 Definitely Related	0

Number of Participants With Grade ≥1 Adverse Events Unlikely or Unrelated to Pembrolizumab Secondary · Date treatment consent signed to date off study, approximately 25 months and 28 days for cohort 1 and 18 months and 12 days for cohort 2.

Abdominal pain

Group	Value	95% CI
Cohort 1: Grade 1 Unlikely Related	0
Cohort 1: Grade 1 Unrelated	2
Cohort 1: Grade 2 Unlikely Related	0
Cohort 1: Grade 2 Unrelated	0
Cohort 1: Grade 3 Unlikely Related	0
Cohort 1: Grade 3 Unrelated	0
Cohort 2: Grade 1 Unlikely Related	1
Cohort 2: Grade 1 Unrelated	1
Cohort 2: Grade 2 Unlikely Related	0
Cohort 2: Grade 2 Unrelated	0
Cohort 2: Grade 3 Unlikely Related	0
Cohort 2: Grade 3 Unrelated	0

Alanine aminotransferase increased

Group	Value	95% CI
Cohort 1: Grade 1 Unlikely Related	0
Cohort 1: Grade 1 Unrelated	2
Cohort 1: Grade 2 Unlikely Related	0
Cohort 1: Grade 2 Unrelated	0
Cohort 1: Grade 3 Unlikely Related	0
Cohort 1: Grade 3 Unrelated	0
Cohort 2: Grade 1 Unlikely Related	0
Cohort 2: Grade 1 Unrelated	1
Cohort 2: Grade 2 Unlikely Related	0
Cohort 2: Grade 2 Unrelated	0
Cohort 2: Grade 3 Unlikely Related	0
Cohort 2: Grade 3 Unrelated	0

Allergic rhinitis

Group	Value	95% CI
Cohort 1: Grade 1 Unlikely Related	0
Cohort 1: Grade 1 Unrelated	1
Cohort 1: Grade 2 Unlikely Related	0
Cohort 1: Grade 2 Unrelated	1
Cohort 1: Grade 3 Unlikely Related	0
Cohort 1: Grade 3 Unrelated	0
Cohort 2: Grade 1 Unlikely Related	0
Cohort 2: Grade 1 Unrelated	0
Cohort 2: Grade 2 Unlikely Related	0
Cohort 2: Grade 2 Unrelated	0
Cohort 2: Grade 3 Unlikely Related	0
Cohort 2: Grade 3 Unrelated	0

Anemia

Group	Value	95% CI
Cohort 1: Grade 1 Unlikely Related	0
Cohort 1: Grade 1 Unrelated	2
Cohort 1: Grade 2 Unlikely Related	0
Cohort 1: Grade 2 Unrelated	0
Cohort 1: Grade 3 Unlikely Related	0
Cohort 1: Grade 3 Unrelated	0
Cohort 2: Grade 1 Unlikely Related	0
Cohort 2: Grade 1 Unrelated	0
Cohort 2: Grade 2 Unlikely Related	1
Cohort 2: Grade 2 Unrelated	0
Cohort 2: Grade 3 Unlikely Related	0
Cohort 2: Grade 3 Unrelated	0

Anorexia

Group	Value	95% CI
Cohort 1: Grade 1 Unlikely Related	0
Cohort 1: Grade 1 Unrelated	0
Cohort 1: Grade 2 Unlikely Related	0
Cohort 1: Grade 2 Unrelated	0
Cohort 1: Grade 3 Unlikely Related	0
Cohort 1: Grade 3 Unrelated	0
Cohort 2: Grade 1 Unlikely Related	0
Cohort 2: Grade 1 Unrelated	0
Cohort 2: Grade 2 Unlikely Related	0
Cohort 2: Grade 2 Unrelated	0
Cohort 2: Grade 3 Unlikely Related	0
Cohort 2: Grade 3 Unrelated	1

Aspartate aminotransferase increased

Group	Value	95% CI
Cohort 1: Grade 1 Unlikely Related	1
Cohort 1: Grade 1 Unrelated	2
Cohort 1: Grade 2 Unlikely Related	0
Cohort 1: Grade 2 Unrelated	0
Cohort 1: Grade 3 Unlikely Related	0
Cohort 1: Grade 3 Unrelated	0
Cohort 2: Grade 1 Unlikely Related	0
Cohort 2: Grade 1 Unrelated	0
Cohort 2: Grade 2 Unlikely Related	0
Cohort 2: Grade 2 Unrelated	0
Cohort 2: Grade 3 Unlikely Related	0
Cohort 2: Grade 3 Unrelated	0

Back pain

Group	Value	95% CI
Cohort 1: Grade 1 Unlikely Related	0
Cohort 1: Grade 1 Unrelated	2
Cohort 1: Grade 2 Unlikely Related	0
Cohort 1: Grade 2 Unrelated	0
Cohort 1: Grade 3 Unlikely Related	0
Cohort 1: Grade 3 Unrelated	0
Cohort 2: Grade 1 Unlikely Related	0
Cohort 2: Grade 1 Unrelated	0
Cohort 2: Grade 2 Unlikely Related	0
Cohort 2: Grade 2 Unrelated	0
Cohort 2: Grade 3 Unlikely Related	0
Cohort 2: Grade 3 Unrelated	0

Blood bilirubin increased

Group	Value	95% CI
Cohort 1: Grade 1 Unlikely Related	0
Cohort 1: Grade 1 Unrelated	1
Cohort 1: Grade 2 Unlikely Related	0
Cohort 1: Grade 2 Unrelated	1
Cohort 1: Grade 3 Unlikely Related	0
Cohort 1: Grade 3 Unrelated	0
Cohort 2: Grade 1 Unlikely Related	0
Cohort 2: Grade 1 Unrelated	1
Cohort 2: Grade 2 Unlikely Related	0
Cohort 2: Grade 2 Unrelated	0
Cohort 2: Grade 3 Unlikely Related	0
Cohort 2: Grade 3 Unrelated	0

Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0) Secondary · Date treatment consent signed to date off study, approximately 25 months and 28 days for cohort 1 and 18 months and 12 days for cohort 2.

Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one

Group	Value	95% CI
Cohort 1: Cancer Vaccine	13
Cohort 2: Participants That Have Had No Vaccine	4

Adverse events — posted to ClinicalTrials.gov

Time frame: Date treatment consent signed to date off study, approximately 25 months and 28 days for cohort 1 and 18 months and 12 days for cohort 2.. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Cohort 1: Cancer Vaccine

Serious: 2/13 (15%)

Deaths: 0/13

Cohort 2: Participants That Have Had No Vaccine

Serious: 2/4 (50%)

Deaths: 2/4

Serious adverse events (6 terms)

Reaction	System	Cohort 1: Cancer Vaccine	Cohort 2: Participants Tha…
Acute kidney injury	Renal and urinary disorders	—	—
Headache	Nervous system disorders	—	—
Renal and urinary disorders - Other, Acute interstitial nephritis	Renal and urinary disorders	—	—
Upper respiratory infection	Infections and infestations	—	—
Dehydration	Metabolism and nutrition disorders	—	—
Hearing impaired	Ear and labyrinth disorders	—	—

Other adverse events (83 terms — click to expand)

Reaction	System	Cohort 1: Cancer Vaccine	Cohort 2: Participants Tha…
Hypocalcemia	Metabolism and nutrition disorders	—	—
Fatigue	General disorders	—	—
Pain	General disorders	—	—
Rash acneiform	Skin and subcutaneous tissue disorders	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—
Lymphocyte count decreased	Investigations	—	—
Diarrhea	Gastrointestinal disorders	—	—
Hyponatremia	Metabolism and nutrition disorders	—	—
Pain in extremity	General disorders	—	—
Rash maculo-papular	Skin and subcutaneous tissue disorders	—	—
Abdominal pain	Gastrointestinal disorders	—	—
Alanine aminotransferase increased	Investigations	—	—
Aspartate aminotransferase increased	Investigations	—	—
Dry skin	Skin and subcutaneous tissue disorders	—	—
Headache	Nervous system disorders	—	—
Hyperuricemia	Metabolism and nutrition disorders	—	—
Hypokalemia	Metabolism and nutrition disorders	—	—
Neck pain	Musculoskeletal and connective tissue disorders	—	—
Upper respiratory infection	Infections and infestations	—	—
Allergic rhinitis	Respiratory, thoracic and mediastinal disorders	—	—
Anemia	Blood and lymphatic system disorders	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—
CPK increased	Investigations	—	—
Creatinine increased	Investigations	—	—
Dizziness	Nervous system disorders	—	—
Dry eye	Eye disorders	—	—
Edema limbs	General disorders	—	—
Eye pain	Eye disorders	—	—
Generalized muscle weakness	Musculoskeletal and connective tissue disorders	—	—
Hyperglycemia	Metabolism and nutrition disorders	—	—
Nasal congestion	Respiratory, thoracic and mediastinal disorders	—	—
Nausea	Gastrointestinal disorders	—	—
Neutrophil count decreased	Investigations	—	—
White blood cell decreased	Investigations	—	—
Acute kidney injury	Renal and urinary disorders	—	—
Anorexia	Metabolism and nutrition disorders	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—
Blood bilirubin increased	Investigations	—	—
Buttock pain	Musculoskeletal and connective tissue disorders	—	—
Cataract	Eye disorders	—	—

Most-reported serious reactions: Acute kidney injury, Headache, Renal and urinary disorders - Other, Acute interstitial nephritis, Upper respiratory infection, Dehydration, Hearing impaired.

Data from ClinicalTrials.gov NCT03072160 adverse events section.

Sponsor's own description

Background: Medullary thyroid cancer (MTC) is a tumor of the thyroid gland. Surgery is the only current treatment to cure it. The drug pembrolizumab (MK-3475) is a new type of cancer therapy. It works by allowing the immune system to detect and kill tumor cells. Objective: To test how pembrolizumab affects people with MTC and if it can offer them clinical benefit. Eligibility: People ages 18 and older with MTC Patients who have recurrent or metastatic MTC, for whom surgery is not a curative option Patients with some imaging evidence of MTC Patients with minimal symptoms related to MTC Design: Participants will be screened with: * Medical history * Physical exam * Blood, urine, and heart tests * Computed tomography (CT) scan or magnetic resonance imaging (MRI): They lie in a machine that takes pictures of the body. * Bone scan Participants will be put in a group based on their treatment history: * Group 1 if they have had an immune stimulating cancer vaccine * Group 2 if they have had no vaccine Participants will receive the study drug as a 30-minute intravenous (IV) infusion every 3 weeks. Treatment will continue for up to 2 years as long as they tolerate it and their disease does not get worse. Participants will have physical exams and blood tests on the day of each infusion. They will have CT and bone scans every 3 months. Participants may save biopsies before treatment and after starting treatment. Participants will have a final visit 3-4 weeks after stopping treatment. This will include a physical exam and blood and heart tests. After this study, participants can join a long-term follow-up study.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
Cohen EEW, Bell RB, Bifulco CB, Burtness B, et al · · 2019 · cited 528× · PMID 31307547 · DOI 10.1186/s40425-019-0662-5
Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond.
Cabanillas ME, Ryder M, Jimenez C. · · 2019 · cited 247× · PMID 31322645 · DOI 10.1210/er.2019-00007
Updates on the Management of Thyroid Cancer.
Araque KA, Gubbi S, Klubo-Gwiezdzinska J. · · 2020 · cited 115× · PMID 32040962 · DOI 10.1055/a-1089-7870
The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition.
Varricchi G, Loffredo S, Marone G, Modestino L, et al · · 2019 · cited 78× · PMID 31412566 · DOI 10.3390/ijms20163934
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice.
Tirrò E, Martorana F, Romano C, Vitale SR, et al · · 2019 · cited 63× · PMID 31540307 · DOI 10.3390/genes10090709
Medullary Thyroid Cancer: Updates and Challenges.
Gild ML, Clifton-Bligh RJ, Wirth LJ, Robinson BG. · · 2023 · cited 59× · PMID 37204852 · DOI 10.1210/endrev/bnad013
Current Guidelines for Management of Medullary Thyroid Carcinoma.
Kim M, Kim BH. · · 2021 · cited 55× · PMID 34154310 · DOI 10.3803/enm.2021.1082
Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities.
Lorusso L, Cappagli V, Valerio L, Giani C, et al · · 2021 · cited 51× · PMID 33803747 · DOI 10.3390/ijms22063117

Verify or expand the search:

Other trials of Pembrolizumab

Trials testing the same drug.

NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07275216 — Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Stand · Phase 2 · not yet recruiting
NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT06724042 — Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors · Phase 1 · not yet recruiting
NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting

Other recruiting trials for Medullary Thyroid Cancer (MTC)

Currently open trials in the same condition.

NCT07142005 — Cultural Adaptation of an Educational Tool in Medullary Thyroid Cancer · recruiting

Other National Cancer Institute (NCI) trials

Trials by the same sponsor.

NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03072160 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
Last refreshed: 11 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03072160.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing